Medicine and Health Sciences Commons^™

Anti-Sars-Cov-2 Monoclonal Antibodies For Early Covid-19: A Real-World Experience, Katherine Belden, Md, Bryan Hess, Md, Caroline Brugger, Crnp, Rachel Carr, Pa, Todd Braun, Md, Joseph Derose, Do, John Zurlo, Md

Division of Infectious Diseases and Environmental Medicine Posters

Higher rates of COVID-19 related hospitalization and death are reported in patients with underlying health conditions and advanced age as compared to the general population.While polyclonal immunity generated by vaccines has demonstrated protection against severe disease, vaccine response takes time and may be inadequate in some high-risk populations.1 Treatment with anti-SARS-CoV-2 neutralizing monoclonal antibodies affords prompt, passive humoral immunity and has been shown in randomized, controlled trials to reduce rates of hospitalization and death from COVID-19 in high-risk ambulatory patients treated early in the course of infection.2,3 The U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization for …